Cat. No.: SCELL-36130

Human wild-type SkBr3 cell line

Description Human wild-type SkBr3 cell line is edited by our special CRISPR/Cas9 technology. SK-BR-3 cells were isolated in 1970 from pleural effusion cells of a 43-year-old, White, female adenocarcinoma patient with blood type A+ who had been treated with radiation, steroids, cytoxan, and 5-fluorouracil.
Size 1 vial (2*106 cells/vial)
Parental Cell Line SkBr3
Biosafety Level 1
Fromat Frozen
Culture Conditions Cells are adherent cells that are cultured at 37°C in a humidified atmosphere with 5% CO2.
Subculture Conditions 1:2 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37℃
Freezing Medium Cells are adherent cells that are cultured at 37°C in a humidified atmosphere with 5% CO2.
Subculture Guidelines All seeding densities should be based on cell counts obtained by established methods.
The recommended seeding density is 2*104 cells/cm2.
If necessary, a partial replacement of the medium 24 hours before subculture may help promote growth.
When the cells achieve 80-90% confluence, they should be passaged.
Knockout Validation Sanger Sequencing
Viability >95% viability before freezing.
Adherent /Suspension Adherent
Disease Ductal carcinoma
Purity Immunogen affinity purified
Storage Vapor phase of liquid nitrogen
Sterility Bacteria: Negative
Yeast: Negative
Mycoplasma: Negative
Applications For research use only
Shipping Info Dry Ice
Species Human
Tissue Breast; Mammary gland
Recommended Control Human wild-type SkBr3 cell line
Doubling Time Ca. 2-3 days
Morphology Epithelial cell
Karyotype This is a hypertriploid human cell line with 84 chromosomes
Pathogens HIV: Negative
Hepatitis B: Negative
Hepatitis C: Negative
Product Type Knockout Stable Cell Line
Price Inquiry
About Us

Creative Bioarray is the world leading biological company whose mission focuses on the acquisition, authentication, production, and development of standard reference microbial strains, and cell lines.

Contact Us
  • (USA)
  • (Europe)
Address
  • USA
  • Germany
Copyright © Creative Bioarray. All rights reserved.